Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Abexinostat
Synonyms
Therapy Description

Abexinostat (PCI-24781) is an HDAC inhibitor, which induces tumor cell apoptosis and decreases tumor cell growth (PMID: 16731764, PMID: 25520806).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Abexinostat PCI-24781|S-78454|CRA-024781 HDAC Inhibitor 38 Abexinostat (PCI-24781) is an HDAC inhibitor, which induces tumor cell apoptosis and decreases tumor cell growth (PMID: 16731764, PMID: 25520806).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown follicular lymphoma not applicable Abexinostat Phase II Actionable In a Phase II clinical trial, Abexinostat treatment reduced tumor size in 86% (12/14) of follicular lymphoma patients with an observed response rate of 64.3% (9/14) and median progression-free survival of 20.5 months (PMID: 26482040). 26482040
Unknown unknown lymphoma not applicable Abexinostat Phase II Actionable In a Phase II trial, patients with T-cell lymphoma demonstrated an overall response rate of 40% (6/15) and a median duration response of 11.5 months when treated with Abexinostat (PCI-24781) (PMID: 28126962). 28126962
Unknown unknown mantle cell lymphoma not applicable Abexinostat Phase II Actionable In a Phase II clinical trial, Abexinostat treatment resulted in an overall response rate of 27.3% (3/11) mantle cell lymphoma patients with a median progression-free survival of 3.9 months (PMID: 26482040). 26482040
Unknown unknown epithelioid sarcoma not applicable Abexinostat Preclinical - Cell line xenograft Actionable In a preclinical study, Abexinostat (PCI-24781) inhibited growth and colony formation of epithelioid sarcoma cell lines in culture, and inhibited tumor growth in epithelioid sarcoma cell line xenograft models (PMID: 26396249). 26396249
Unknown unknown hematologic cancer not applicable Abexinostat Phase II Actionable In a Phase II trial, treatment with Abexinostat (PCI-24781) in patients with a variety of hematological cancers resulted in an overall response rate (ORR) of 28% (24/87), a complete response in 5%, and a median duration response of 8.8 months (PMID: 28126962). 28126962
Unknown unknown diffuse large B-cell lymphoma not applicable Abexinostat Phase II Actionable In a Phase II trial, patients with diffuse large B-cell lymphoma demonstrated an overall response rate of 31% (5/16) and a median duration response of 1.9 months when treated with Abexinostat (PCI-24781) (PMID: 28126962). 28126962

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT03600441 Phase II Abexinostat Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER) Active, not recruiting


Additional content available in CKB BOOST